Clinical trials and the origins of pharmaceutical fraud : Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism
This paper describes one possible origin point for fraudulent behavior within the American pharmaceutical industry. We argue that during the late nineteenth century therapeutic reformers sought to promote both laboratory science and increasingly systematized forms of clinical experiment as a new basis for therapeutic knowledge. This process was intertwined with a transformation in the ethical framework in which medical science took place, one in which monopoly status was replaced by clinical utility as the primary arbiter of pharmaceutical legitimacy. This new framework fundamentally altered the set of epistemic virtues-a phrase we draw from the philosophical field of virtue epistemology-considered necessary to conduct reliable scientific inquiry regarding drugs. In doing so, it also made possible new forms of fraud in which newly emergent epistemic virtues were violated. To make this argument, we focus on the efforts of Francis E. Stewart and George S. Davis of Parke, Davis & Company. Therapeutic reformers within the pharmaceutical industry, such as Stewart and Davis, were an important part of the broader normative and epistemic transformation we describe in that they sought to promote laboratory science and systematized clinical trials toward the twin goals of improving pharmaceutical science and promoting their own commercial interests. Yet, as we suggest, Parke, Davis & Company also serves as an example of a company that violated the very norms that Stewart and Davis helped introduce. We thus seek to describe one possible origin point for the widespread fraudulent practices that now characterize the pharmaceutical industry. We also seek to describe an origin point for why we conceptualize such practices as fraudulent in the first place.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:58 |
|---|---|
| Enthalten in: |
History of science - 58(2020), 4 vom: 14. Dez., Seite 533-558 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gabriel, Joseph M [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.05.2021 Date Revised 31.05.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1177/0073275320942435 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312891334 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312891334 | ||
| 003 | DE-627 | ||
| 005 | 20231225145403.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/0073275320942435 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1042.xml |
| 035 | |a (DE-627)NLM312891334 | ||
| 035 | |a (NLM)32713203 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Gabriel, Joseph M |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical trials and the origins of pharmaceutical fraud |b Parke, Davis & Company, virtue epistemology, and the history of the fundamental antagonism |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.05.2021 | ||
| 500 | |a Date Revised 31.05.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a This paper describes one possible origin point for fraudulent behavior within the American pharmaceutical industry. We argue that during the late nineteenth century therapeutic reformers sought to promote both laboratory science and increasingly systematized forms of clinical experiment as a new basis for therapeutic knowledge. This process was intertwined with a transformation in the ethical framework in which medical science took place, one in which monopoly status was replaced by clinical utility as the primary arbiter of pharmaceutical legitimacy. This new framework fundamentally altered the set of epistemic virtues-a phrase we draw from the philosophical field of virtue epistemology-considered necessary to conduct reliable scientific inquiry regarding drugs. In doing so, it also made possible new forms of fraud in which newly emergent epistemic virtues were violated. To make this argument, we focus on the efforts of Francis E. Stewart and George S. Davis of Parke, Davis & Company. Therapeutic reformers within the pharmaceutical industry, such as Stewart and Davis, were an important part of the broader normative and epistemic transformation we describe in that they sought to promote laboratory science and systematized clinical trials toward the twin goals of improving pharmaceutical science and promoting their own commercial interests. Yet, as we suggest, Parke, Davis & Company also serves as an example of a company that violated the very norms that Stewart and Davis helped introduce. We thus seek to describe one possible origin point for the widespread fraudulent practices that now characterize the pharmaceutical industry. We also seek to describe an origin point for why we conceptualize such practices as fraudulent in the first place | ||
| 650 | 4 | |a Historical Article | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a & Company | |
| 650 | 4 | |a Davis | |
| 650 | 4 | |a Francis Stewart | |
| 650 | 4 | |a George Davis | |
| 650 | 4 | |a Parke | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a corruption | |
| 650 | 4 | |a historical epistemology | |
| 650 | 4 | |a history of medicine | |
| 650 | 4 | |a history of science | |
| 650 | 4 | |a pharmaceutical industry | |
| 650 | 4 | |a philosophy of science | |
| 650 | 4 | |a virtue epistemology | |
| 650 | 7 | |a Nonprescription Drugs |2 NLM | |
| 700 | 1 | |a Holman, Bennett |e verfasserin |4 aut | |
| 700 | 1 | |a Stewart, Francis |e erwähnter |4 oth | |
| 700 | 1 | |a Davis, George |e erwähnter |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t History of science |d 1969 |g 58(2020), 4 vom: 14. Dez., Seite 533-558 |w (DE-627)NLM115022600 |x 1753-8564 |7 nnns |
| 773 | 1 | 8 | |g volume:58 |g year:2020 |g number:4 |g day:14 |g month:12 |g pages:533-558 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/0073275320942435 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 58 |j 2020 |e 4 |b 14 |c 12 |h 533-558 | ||